Europe Q1 Earnings: Sector Divergence Widens as Bank Credit Costs Surge and Defence Orders Explode

Core Thesis

European Q1 earnings reveal an unusually wide sector dispersion. Banks face a simultaneous triple squeeze – net interest income stagnation, loan loss provisions rising 30–77% year-on-year, and CET1 ratios eroding – while aerospace & defence and select reinsurers post results that substantially beat consensus. Consumer staples and medtech are underperforming on structural demand weakness and policy headwinds. The market is underestimating the persistence of defence order momentum and the severity of bank credit deterioration.

Banks: Credit Cycle Turning, Capital Buffers Shrinking

Conclusion: Banking profitability is deteriorating faster than consensus recognised. Net interest income is flat to slightly positive, but credit costs are accelerating and capital positions are weakening.

Evidence: HSBC 1Q26 impairment charges rose 60% year-on-year, CET1 dropped from 14.9% to 13.7%. Monte Paschi saw credit costs surge 76.9% year-on-year, CET1 from 19.7% to 15.9%. UniCredit NII grew only 3%, CET1 fell from 16.1% to 14.3% due to consolidation. BPER loan impairment increased 33.7%. Across the sector, NII is broadly flat or negative in real terms, while the cost of risk is structurally higher. Small and mid-tier banks (Banco BPM, Unicaja) show the sharpest earnings volatility.

Investment implication: Favour large-cap diversified banks with strong fee income (UniCredit, Intesa) over smaller names. The current consensus does not fully price a multi-quarter credit upcycle; any guidance downgrade on NIM or provisions will pressure underweight-rated names.

Aerospace & Defence: Order Growth Structural, Not Cyclical

Conclusion: Defence order intake is accelerating far beyond normal replacement cycles; the backlog is building sustainably.

Evidence: Hensoldt 1Q26 orders reached €1,357m (+94% year-on-year), with optronics orders surging +1,263% driven by Shakal and Puma programmes. The book-to-bill ratio stood at 2.8x. Leonardo orders hit €7.9bn (+15%), free cash flow improved seasonally to -€450m from -€580m. The optical division’s margin recovered from 1.7% to 12% as new plant ramp-up improved.

Investment implication: The order trajectory supports multi-year revenue visibility. Hensoldt’s EBITDA margin expansion of ~200bp year-on-year validates execution improvements. Overweight-rated Leonardo benefits from both order growth and cash flow improvement.

Reinsurance: Underwriting Margin Beats Consensus by a Wide Margin

Conclusion: Property & casualty reinsurance combined ratios are materially better than targets and consensus, driven by lower natural catastrophe losses and disciplined risk selection.

Evidence: Swiss Re 1Q26 P&C combined ratio of 79.9% versus consensus 82.4% and its own target of <85%. Natural catastrophe losses fell 50% year-on-year to $100m. Scor P&C combined ratio of 83.3% was slightly worse than consensus 82.9%, but the nat cat ratio improved from 12.5% to 2.0%. Both companies saw improved investment income and solvency ratios (Scor 219% vs 212% year-on-year).

Investment implication: Swiss Re’s COR beat suggests structural underwriting improvement, not just benign weather. The sector trades at undemanding valuations relative to earnings momentum. Overweight-rated names should benefit from positive revisions.

Consumer Staples & Leisure: Demand Weaker Than Headline Metrics Suggest

Conclusion: Underlying volume and spend trends in alcohol and UK pub segments are significantly softer than consensus models.

Evidence: Diageo 3Q26 organic sales growth of -4.2% versus consensus -2.3%, with North America particularly weak at -13.6% (consensus -10.0%). JD Wetherspoon FY26 PBT consensus has been cut 13–14% since January; Q3 like-for-like sales of +3.0% are below historical trends and show deceleration post-H1. ABI’s 1Q26 organic volume was -0.6%, slightly below consensus -0.5%.

Investment implication: UK consumer exposure remains hazardous. Diageo’s North American weakness is not transient; it reflects inventory destocking and share loss. Avoid JD Wetherspoon until PBT expectations stabilise.

MedTech: China VBP and US Pricing Pressure Dominate

Conclusion: The medtech sector faces a broad-based earnings headwind: eight of 11 companies tracked by MS have operating profit below consensus.

Evidence: DiaSorin 1Q26 organic growth -2.3%, operating margin 22.8%. Siemens Healthineers organic +3.2% but facing tough comparatives. Tecan operating profit 11.8% below consensus. Demant benefited from Oticon Zeal launch but overall sector margins are compressed by China VBP, US skin substitute pricing, and FX headwinds. Philips diagnostics & treatment segment had a weak start.

Investment implication: Avoid any medtech name without a clear product cycle catalyst. The Chinese VBP cycle is broadening, not peaking. Underweight-rated names (DiaSorin, Tecan) face further downgrade risk.

Key Risks

Middle East conflict could further disrupt air travel demand (IHG ~6% of fees from Middle East, Amadeus FY EBIT at risk), and raise energy costs for transport and chemicals.
US tariffs and inflation pass-through effects on consumer goods, tyres, and industrial raw materials remain underestimated.
China VBP expansion is not limited to medtech; it also affects nutrition (Fresenius Kabi) and diagnostic reagents.
European power market intervention (Italy, Spain) could compress utility earnings, particularly for Enel and Endesa.

Trading Implications

Overweight: Aerospace & defence (Leonardo, Hensoldt), large-cap diversified banks (UniCredit, Intesa), select reinsurance (Swiss Re).
Underweight: UK consumer staples (Diageo, JD Wetherspoon), small/mid-cap banks (Banco BPM, Monte Paschi), medtech exposed to VBP (Tecan, DiaSorin).
Key catalyst: Bank 1Q26 results (5–8 May) will provide the first real test of credit cost assumptions; any material provision beat will trigger sector rotation.

Appendix data (bank pre-tax profit, CET1 details) omitted for length; available in full report.